IMS26: Key readouts rock the multiple myeloma field amid shifting landscape

Data from AbbVie, J&J and BMS grabbed the attention of IMS 2026 attendees as the pharma titans battle for market share in multiple myeloma. Data from AbbVie, J&J and BMS grabbed the attention of IMS 2026 attendees as the pharma titans battle for market share in the multiple myeloma space. The Clinical Trials Arena editorial team brings you the highlights from the IMS 2026 Congress in Glasgow, Scotland. Credit: David A Litman / Shutterstock.com. In recent years, the multiple myeloma space has undergone rapid evolution, with advanced modalities like cell and immunotherapies increasingly moving into earlier lines of treatment as…

Source: Clinical Trials Arena